CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX) (the “Company”), a leading provider of healthcare data and technology products and solutions, today announced that it has signed a definitive agreement to acquire ScienceIO. The transaction has been unanimously approved by the Veradigm Board of Directors and is expected to close as promptly as practicable following the satisfaction of customary closing conditions. Founded in 2019, ScienceIO is a leading AI platform and foundation model provider for h ...

CHICAGO--(BUSINESS WIRE)--Which region of the U.S. has the highest rates of hypertension, coronary artery disease and heart failure? The South, according to this analysis on cardiovascular disease (CVD) from Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions. Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients. The report explores ...

CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education. Influenza vaccination is associated with a lower risk for adverse cardiovascular events, with an overall 34% lower risk of major adverse cardiovascular events and a 45% lower risk among indivi ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company’s Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to t ...

CHICAGO--(BUSINESS WIRE)--The new leadership team at Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, has provided refreshed estimated, unaudited ranges of financial information for fiscal 2023. Dr. Shih-Yin Ho, Interim CEO, and Lee Westerfield, Interim CFO, will discuss Veradigm’s mission, business and operations, and innovation strategy, as well as its estimated financial information for fiscal 2023, at the J.P. Morgan Healthcare Conference on Wednesday, Januar ...

Providers using Veradigm EHRs to gain access to longitudinal patient records, improving interoperability and driving better treatment decisions FISHKILL, N.Y. and CHICAGO, Ill., Jan. 9, 2024 /PRNewswire/ -- MedAllies, a leading healthcare interoperability and connectivity services provider, announced today that Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology services, has selected MedAllies as its Qualified Health Information Network (QHIN) partner. The effort will enable ...

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ:MDRX). About the Investigation A securities class action has been filed in U.S. District Court in the Northern District of Illinois on behalf of purchasers of Veradigm common stock between February 26, 2021 and June 13, 2023, inclusive (the "Class Period"). The lawsuit asserts violations of the Securi ...

CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market. “Today’s announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio b ...

```markdown PART I. FINANCIAL INFORMATION [Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited consolidated financial statements, detailing financial position, performance, and cash flows, with notes Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $492,597 | $132,517 | | Total current assets | $810,770 | $761,342 | | Goodwill | $523,927 | $506,607 | | Long-term assets attributable to discontinued operations | $0 | $793,156 | | **Total assets** | **$1,690,659** | **$2,425,229** | | **Liabilities & Equity** | | | | Total current liabilities | $253,091 | $547,082 | | Long-term debt | $200,326 | $350,062 | | **Total liabilities** | **$513,636** | **$1,017,091** | | **Total stockholders' equity** | **$1,177,023** | **$1,408,138** | Consolidated Statements of Operations For the third quarter of 2022, revenue from continuing operations grew **5.0%** year-over-year to **$151.9 million**, with income from continuing operations at **$10.9 million** Q3 2022 vs Q3 2021 Performance (in thousands) | Metric | Q3 2022 | Q3 2021 | | :--- | :--- | :--- | | Total Revenue | $151,922 | $144,668 | | Gross Profit | $83,436 | $69,640 | | Income from Operations | $25,001 | $18,484 | | Income from Continuing Operations | $10,925 | $20,276 | | Net Income (Loss) | $14,528 | $16,180 | Nine Months 2022 vs 2021 Performance (in thousands) | Metric | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | | Total Revenue | $445,492 | $419,526 | | Gross Profit | $236,399 | $200,976 | | Income from Operations | $26,217 | $43,031 | | Income from Continuing Operations | $32,658 | $50,719 | | Net (Loss) Income | $(26,641) | $47,163 | Consolidated Statements of Cash Flows For the nine months ended September 30, 2022, net cash provided by operating activities was **$95.8 million**, a significant improvement from the **$140.5 million** used in the prior-year period Cash Flow Summary - Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $95,767 | $(140,473) | | Net cash provided by (used in) investing activities | $603,719 | $(54,872) | | Net cash used in financing activities | $(387,374) | $(125,320) | | **Net increase (decrease) in cash** | **$311,384** | **$(321,145)** | Notes to Consolidated Financial Statements The notes provide detailed explanations of accounting policies and financial statement components, including convertible debt, revenue recognition, acquisitions, divestitures, and stock repurchases - Total unsatisfied performance obligations were **$989 million** as of September 30, 2022, with approximately **41%** expected to be recognized over the next 12 months[38](index=38&type=chunk) - The company acquired Babel Health for a net cash payment of **$24.5 million** on March 25, 2022, included in the Veradigm segment[57](index=57&type=chunk) - The company completed the sale of its Hospitals and Large Physician Practices Business for **$670.0 million** in cash, plus up to **$30.0 million** in contingent consideration, now reported as a discontinued operation[61](index=61&type=chunk) - The company repurchased **9.7 million shares** for **$177.0 million** under its 2022 stock purchase program during the nine months ended September 30, 2022[84](index=84&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and results of operations, highlighting key performance drivers and strategic impacts Overview of Consolidated Results For Q3 2022, total revenue increased **5.0%** to **$151.9 million**, and gross profit rose **19.8%** to **$83.4 million**, boosting gross margin to **54.9%** Q3 2022 vs Q3 2021 Financial Summary (in thousands) | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Total Revenue | $151,922 | $144,668 | 5.0% | | Gross Profit | $83,436 | $69,640 | 19.8% | | Gross Margin % | 54.9% | 48.1% | - | | Income from Operations | $25,001 | $18,484 | 35.3% | | Net Income (Loss) | $14,528 | $16,180 | (10.2%) | - SG&A expenses increased **18.7%** in Q3 2022, primarily due to higher legal costs and full recognition of corporate expenses previously allocated to the divested business[154](index=154&type=chunk) - Interest expense decreased **65.6%** in Q3 2022 due to lower debt levels and the adoption of ASU 2020-06 for convertible notes[158](index=158&type=chunk)[159](index=159&type=chunk) Segment Operations Following the divestiture of the Hospitals and Large Physician Practices business, the company's operations are now primarily focused on the Veradigm segment Veradigm Segment Performance - Q3 2022 vs Q3 2021 (in thousands) | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $145,391 | $137,169 | 6.0% | | Gross Profit | $78,801 | $65,696 | 19.9% | | Income from Operations | $27,707 | $17,099 | 62.0% | | Operating Margin % | 19.1% | 12.5% | - | - Veradigm's gross profit and margin increased due to higher revenues, lower contractor usage, and improved hosting infrastructure costs[177](index=177&type=chunk) Liquidity and Capital Resources The company's liquidity position is strong, with cash and cash equivalents of **$494 million** and available borrowing capacity of **$699 million** as of September 30, 2022 - Principal liquidity sources as of September 30, 2022, include **$494 million** in cash and cash equivalents and **$699 million** available under the Revolving Facility[183](index=183&type=chunk) Cash Flow Summary - Nine Months Ended Sep 30, 2022 (in thousands) | Activity | Amount | | :--- | :--- | | Net cash provided by operating activities | $95,767 | | Net cash provided by investing activities | $603,719 | | Net cash used in financing activities | $(387,374) | - Future material cash requirements include **$207.9 million** for convertible senior notes, **$19.7 million** for operating leases, and **$38.3 million** in purchase obligations[192](index=192&type=chunk)[193](index=193&type=chunk)[194](index=194&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that there have been no material changes to its market risk disclosures during the nine months ended September 30, 2022 - Market risk disclosures have not changed materially during the nine months ended September 30, 2022[200](index=200&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of September 30, 2022 - The CEO and CFO concluded that disclosure controls and procedures were effective as of September 30, 2022[202](index=202&type=chunk) - No material changes occurred in internal control over financial reporting during Q3 2022[204](index=204&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) This section details ongoing legal contingencies, including civil investigative demands and a settlement related to a deferred prosecution agreement - The company is subject to a civil investigative demand (CID) related to Horizon Clinicals software, with McKesson indemnifying Allscripts for related government payments and defense[115](index=115&type=chunk) - Practice Fusion settled a claimed breach of its Deferred Prosecution Agreement with the U.S. Attorney's Office for **$200,000**, extending the agreement by 11 weeks[116](index=116&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) The company reports no material changes to the risk factors previously disclosed in its Annual Report on Form 10-K - No material changes occurred from the risk factors previously disclosed in the company's Form 10-K[207](index=207&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section discusses the company's stock repurchase activity under its 2022 program, detailing shares repurchased and remaining authorization Stock Repurchase Activity - Q3 2022 | Period (2022) | Total Shares Purchased (thousands) | Average Price Paid Per Share | Total Cost (thousands) | | :--- | :--- | :--- | :--- | | July | 0 | $0.00 | $0 | | August | 1,476 | $17.28 | $25,494 | | September | 481 | $16.87 | $8,126 | | **Total Q3** | **1,957** | **$17.18** | **$33,620** | - Approximately **$73.2 million** remained available for purchase under the 2022 stock repurchase program as of September 30, 2022[210](index=210&type=chunk) [Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including various agreements, CEO and CFO certifications, and Inline XBRL data files ```

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Richard Poulton - CEO Thomas Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Charles Rhyee - Cowen and Company Thomas Keller - RBC Capital Markets George Hill - Deutsche Bank Cynthia Motz - Goldman Sachs Eric Percher - Nephron Research Operator Greetings, and welcome to A ...